Why it matters nowThe synthesized recommendations supply practical frameworks for adjusting national control campaigns, optimizing funding deployment, and mitigating structural impediments that delay disease clearance objectives.
Why it matters nowThe results emphasize the importance of predictable domestic funding, robust monitoring systems, and sustainable local partnerships to maintain endemic disease control during systemic crises.
Why it matters nowThe project is positioned as foundational work for population-based surveillance of praziquantel resistance in Schistosoma, with relevance to monitoring and mitigating persistent hotspots and to novel drugs in development.
Why it matters nowThe study demonstrates that interruption of mass drug administration can lead to rapid recrudescence of urogenital schistosomiasis in hotspot areas. The authors recommend re-intensifying MDA plus additional interventions in hotspots and adapting strategies from mass administration to targeted surveillance-response in low-prevalence areas.
Why it matters nowSchistosomiasis affects nearly 220 million people worldwide, primarily in Sub-Saharan Africa. Current guidelines recommend 75% treatment coverage among school-aged children, yet many programs fall short. High sustained coverage is essential given the risk of reinfection.